Landoni M F, Lees P
Department of Veterinary Basic Sciences, Royal Veterinary College, Hawkshead Campus, Hatfield, Herts, United Kingdom.
Chirality. 1995;7(8):586-97. doi: 10.1002/chir.530070806.
The pharmacokinetics (PK) and pharmacodynamics (PD) of (S)- and (R)-ketoprofen (KTP) enantiomers were studied in calves after intravenous administration of each enantiomer at a dose of 1.5 mg/kg. Pharmacodynamic properties were evaluated using a model of acute inflammation, comprising subcutaneously implanted tissue cages stimulated by intracaveal injection of carrageenan. Chiral inversion of (R)-KTP to the (S)-antipode occurred. The R:S ratio in plasma was 33:1 5 min after administration, decreasing to 1:1 at 8 h. The calculated extent of inversion was 31 +/- 7%. The R:S ratio in inflammatory exudate was of the order 3:1 at all the sampling times and the ratio in transudate was approximately 2:1 for 6 h, declining to 1:1 at 30 h. Only (S)-KTP was detected in biological fluids after administration of this enantiomer. Elimination half-life was longer for the (S) (2.19 h) than the (R)-enantiomer (1.30 h) and volume of distribution was also somewhat higher for the (S)-enantiomer. Body clearance values were 0.119 l/kg/h for (S)-KTP and 0.151 l/kg/h for the (R)-antipode. For (R)-KTP effects obtained were considered as a hybrid, since they potentially reflect the actions of both enantiomers. Concentrations of LTB4 and the cytokines interleukin-1, interleukin-6, and tumor necrosis factor alpha, in exudate were not significantly affected by either (R)- or (S)-KTP treatments. Inhibition of ex vivo thromboxane B2 (TxB2) synthesis, exudate prostaglandin E2 (PGE2) synthesis, beta-glucuronidase release (beta-glu), and bradykinin-induced skin swelling was significant in both treated groups. PK/PD modelling was applied to the (S)-KTP treatment only. EC50 values for inhibition of serum TxB2, exudate PGE2 and beta-glu and BK-induced swelling were 0.047, 0.042, 0.101, and 0.038 microgram/ml, respectively. It is concluded that the low EC50 values for inhibition of TxB2 and PGE2 by (S)-KTP are likely to explain the effects produced by (R)-KTP administration, since concentrations of (S)-KTP in exudate of these calves following chiral inversion were at least 5 times higher than the EC50 at all sampling times. The data for beta-glu and bradykinin-induced swelling inhibition indicate possible inhibitory actions of (R)-KTP as well as (S)-KTP.
在犊牛静脉注射剂量为1.5mg/kg的(S)-酮洛芬(KTP)和(R)-酮洛芬对映体后,研究了它们的药代动力学(PK)和药效动力学(PD)。使用急性炎症模型评估药效学特性,该模型包括通过向腔内注射角叉菜胶刺激皮下植入的组织笼。(R)-KTP发生了向(S)-对映体的手性转化。给药后5分钟血浆中的R:S比值为33:1,8小时时降至1:1。计算得出的转化程度为31±7%。在所有采样时间,炎症渗出液中的R:S比值约为3:1,漏出液中的比值在6小时内约为2:1,30小时时降至1:1。仅给予该对映体后,在生物体液中仅检测到(S)-KTP。(S)-对映体的消除半衰期(2.19小时)比(R)-对映体(1.30小时)长,(S)-对映体的分布容积也略高。(S)-KTP的机体清除率值为0.119l/kg/h,(R)-对映体为0.151l/kg/h。对于(R)-KTP,所获得的效应被认为是一种混合效应,因为它们可能反映了两种对映体的作用。渗出液中白三烯B4(LTB4)以及细胞因子白细胞介素-1、白细胞介素-6和肿瘤坏死因子α的浓度不受(R)-或(S)-KTP处理的显著影响。在两个治疗组中,对体外血栓素B2(TxB2)合成、渗出液前列腺素E2(PGE2)合成、β-葡萄糖醛酸酶释放(β-葡)和缓激肽诱导的皮肤肿胀的抑制均具有显著性。PK/PD建模仅应用于(S)-KTP治疗。抑制血清TxB2、渗出液PGE2和β-葡以及缓激肽诱导肿胀的EC50值分别为0.047、0.042、0.101和0.038μg/ml。得出的结论是,(S)-KTP对TxB2和PGE2抑制的低EC50值可能解释了给予(R)-KTP所产生的效应,因为这些犊牛在发生手性转化后渗出液中(S)-KTP的浓度在所有采样时间至少比EC50高5倍。β-葡和缓激肽诱导肿胀抑制的数据表明(R)-KTP以及(S)-KTP可能具有抑制作用。